Department of Health and Exercise Science, Colorado State University, Fort Collins, CO 80523-1582, USA.
Med Sci Sports Exerc. 2010 Apr;42(4):739-44. doi: 10.1249/MSS.0b013e3181bcab6c.
Epigallocatechin-3-gallate (EGCG), a component of green tea, increases endurance performance in animals and promotes fat oxidation during cycle ergometer exercise in adult humans.
We have investigated the hypothesis that short-term consumption of EGCG delays the onset of the ventilatory threshold (VT) and increases maximal oxygen uptake (VO2max).
In this randomized, repeated-measures, double-blind study, 19 healthy adults (11 males and 8 females, age = 26 ± 2 yr (mean ± SE)) received seven placebo or seven EGCG (135-mg) pills. Forty-eight hours before data collection, participants began consuming three pills per day; the last pill was taken 2 h before exercise testing. VT and VO2max were determined from breath-by-breath indirect calorimetry data collected during continuous incremental stationary cycle ergometer exercise (20-35 W·min(-1)), from rest until volitional fatigue. Each condition/exercise test was separated by a minimum of 14 d.
Compared with placebo, short-term EGCG consumption increased VO2max (3.123 ± 0.187 vs 3.259 ± 0.196 L·min(-1), P = 0.04). Maximal work rate (301 ± 15 vs 301 ± 16 W, P = 0.98), maximal RER (1.21 ± 0.01 vs 1.22 ± 0.02, P = 0.27), and maximal HR were unaffected (180 ± 3 vs 180 ± 3 beats·min(-1), P = 0.87). In a subset of subjects (n = 11), maximal cardiac output (determined via open-circuit acetylene breathing) was also unaffected by EGCG (29.6 ± 2.2 vs 30.2 ± 1.4 L·min(-1), P = 0.70). Contrary to our hypothesis, EGCG decreased VO2 at VT (1.57 ± 0.11 vs 1.48 ± 0.10 L·min(-1)), but this change was not significant (P = 0.06).
Short-term consumption of EGCG increased VO2max without affecting maximal cardiac output, suggesting that EGCG may increase arterial-venous oxygen difference.
表没食子儿茶素没食子酸酯(EGCG)是绿茶的一种成分,可提高动物的耐力表现,并促进成人在进行踏车运动时的脂肪氧化。
我们假设短期摄入 EGCG 会延迟呼吸阈(VT)的出现,并增加最大摄氧量(VO2max)。
在这项随机、重复测量、双盲研究中,19 名健康成年人(11 名男性和 8 名女性,年龄=26±2 岁(平均值±SE))分别接受了 7 次安慰剂或 7 次 EGCG(135mg)丸剂。在收集数据的 48 小时前,参与者开始每天服用 3 丸;最后一次服药在运动测试前 2 小时。VT 和 VO2max 通过在连续递增固定踏车测力计运动(20-35W·min(-1))期间收集的呼吸到呼吸间接热量测定数据来确定,从休息到自愿疲劳。每种情况/运动测试之间至少间隔 14 天。
与安慰剂相比,短期 EGCG 摄入增加了 VO2max(3.123±0.187 与 3.259±0.196 L·min(-1),P=0.04)。最大工作率(301±15 与 301±16 W,P=0.98)、最大 RER(1.21±0.01 与 1.22±0.02,P=0.27)和最大 HR 不受影响(180±3 与 180±3 次·min(-1),P=0.87)。在一组受试者(n=11)中,最大心输出量(通过开路乙炔呼吸测定)也不受 EGCG 影响(29.6±2.2 与 30.2±1.4 L·min(-1),P=0.70)。与我们的假设相反,EGCG 降低了 VT 时的 VO2(1.57±0.11 与 1.48±0.10 L·min(-1)),但这种变化没有统计学意义(P=0.06)。
短期摄入 EGCG 可增加 VO2max,而不影响最大心输出量,这表明 EGCG 可能会增加动静脉氧差。